Abstract

Background and aim

Retinopathy of prematurity (ROP) is the major ocular problem of preterm infants that occurs with abnormal proliferation of immature retinal vessels. Although pentoxifylline (PTX) was reported to inhibit vasculogenesis and neovascularization in experimental studies, there is no clinical data about the effects of PTX treatment on the development and severity of ROP. This clinical study aimed to investigate the possible effects of PTX on the development of ROP.

Materials and methods

A single-centre retrospective study was conducted including preterm infants who were hospitalised in the neonatal intensive care unit between 2015–2017 years. Infants were divided into two groups in terms of PTX administration for adjuvant therapy, as PTX and non-PTX groups.

Results

A total of 211 infants were included in the study [gestational age 29 (27–31) weeks, birth weight 1140 (960–1340) g]. From these, 97 infants (46%) were given PTX treatment. The two groups were similar in terms of demographic data and baseline clinical characteristics. Any stage of ROP was detected in 47.4% of infants in the PTX group, which was significantly higher than those in the non-PTX group (27.2%) (p = 0.002). The incidence of advanced-stage ROP in the PTX group (10.3%) was also higher than in the non-PTX group (2.6%) (p = 0.021). Repeated usage of PTX was not found to be related to the development of ROP (p = 0.059). The time of PTX administration was similar between the ROP and no-ROP groups (median; one vs one week, p = 0.825). Surfactant therapy, duration of hospital stay, and PTX treatment were found as significant risk factors for ROP in the logistic regression analysis.

Conclusions

In contrast to the experimental studies and also promising results of PTX treatment in some neonatal morbidities, it may be associated with increased incidence and stage of ROP.

中文翻译：

---

己酮可可碱对早产儿视网膜病变发展和严重程度的可能影响

摘要

背景和目标

早产儿视网膜病变 (ROP) 是早产儿的主要眼部问题，伴随着未成熟视网膜血管的异常增殖而发生。尽管在实验研究中报告己酮可可碱 (PTX) 抑制血管生成和新生血管形成，但没有关于 PTX 治疗对 ROP 的发展和严重程度的影响的临床数据。本临床研究旨在调查 PTX 对 ROP 发展的可能影响。

材料和方法

对 2015-2017 年间在新生儿重症监护病房住院的早产儿进行了一项单中心回顾性研究。婴儿在辅助治疗的 PTX 给药方面分为两组，即 PTX 组和非 PTX 组。

结果

共有 211 名婴儿被纳入研究 [胎龄 29 (27-31) 周，出生体重 1140 (960-1340) g]。其中，97 名婴儿 (46%) 接受了 PTX 治疗。两组在人口统计数据和基线临床特征方面相似。PTX组47.4%的婴儿检测到任何阶段的ROP，显着高于非PTX组（27.2%）（p  = 0.002）。PTX 组晚期 ROP 的发生率（10.3%）也高于非 PTX 组（2.6%）（p  = 0.021）。没有发现重复使用 PTX 与 ROP 的发展有关 ( p  = 0.059)。ROP 组和无 ROP 组的 PTX 给药时间相似（中位数；1 周 vs 1 周，p = 0.825)。在逻辑回归分析中发现表面活性剂治疗、住院时间和 PTX 治疗是 ROP 的重要危险因素。

结论

与实验研究和 PTX 治疗在某些新生儿疾病中的有希望的结果相反，它可能与 ROP 的发病率和阶段增加有关。